1. Home
  2. AADI vs BMTX Comparison

AADI vs BMTX Comparison

Compare AADI & BMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AADI
  • BMTX
  • Stock Information
  • Founded
  • AADI 2011
  • BMTX 2015
  • Country
  • AADI United States
  • BMTX United States
  • Employees
  • AADI 70
  • BMTX N/A
  • Industry
  • AADI Biotechnology: Pharmaceutical Preparations
  • BMTX Major Banks
  • Sector
  • AADI Health Care
  • BMTX Finance
  • Exchange
  • AADI Nasdaq
  • BMTX Nasdaq
  • Market Cap
  • AADI 51.7M
  • BMTX 40.4M
  • IPO Year
  • AADI N/A
  • BMTX N/A
  • Fundamental
  • Price
  • AADI $2.10
  • BMTX $3.30
  • Analyst Decision
  • AADI Hold
  • BMTX Strong Buy
  • Analyst Count
  • AADI 3
  • BMTX 2
  • Target Price
  • AADI $1.75
  • BMTX $6.70
  • AVG Volume (30 Days)
  • AADI 102.0K
  • BMTX 18.9K
  • Earning Date
  • AADI 11-06-2024
  • BMTX 11-18-2024
  • Dividend Yield
  • AADI N/A
  • BMTX N/A
  • EPS Growth
  • AADI N/A
  • BMTX N/A
  • EPS
  • AADI N/A
  • BMTX N/A
  • Revenue
  • AADI $23,817,000.00
  • BMTX $57,962,000.00
  • Revenue This Year
  • AADI $4.79
  • BMTX $6.32
  • Revenue Next Year
  • AADI $10.72
  • BMTX $2.91
  • P/E Ratio
  • AADI N/A
  • BMTX N/A
  • Revenue Growth
  • AADI 10.57
  • BMTX N/A
  • 52 Week Low
  • AADI $1.21
  • BMTX $1.45
  • 52 Week High
  • AADI $5.70
  • BMTX $3.91
  • Technical
  • Relative Strength Index (RSI)
  • AADI 63.80
  • BMTX 52.55
  • Support Level
  • AADI $1.90
  • BMTX $3.10
  • Resistance Level
  • AADI $2.17
  • BMTX $3.44
  • Average True Range (ATR)
  • AADI 0.09
  • BMTX 0.16
  • MACD
  • AADI 0.00
  • BMTX -0.01
  • Stochastic Oscillator
  • AADI 70.49
  • BMTX 52.63

About AADI Aadi Bioscience Inc.

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

About BMTX BM Technologies Inc.

BM Technologies Inc provides digital banking and disbursement services to consumers and students nationwide through a full-service fintech banking platform, accessible to customers anywhere and anytime through digital channels. It facilitates deposits and banking services between a customer and its Partner Bank, Customers Bank, which is a related party and is a Federal Deposit Insurance Corporation (FDIC) insured bank. The company has four primary revenue sources: interchange and card revenue, servicing fees, account fees, and university fees. The majority of revenues are driven by customer activity (deposits, spending, transactions, etc.) and may be paid or passed through by customer banks, universities, or paid directly by customers.

Share on Social Networks: